samedan logo

 
 
spacer
home > white papers > Data Technology as a Catalyst for Growth in the Life Sciences - Aigenpulse
WHITE PAPERS
logo_Aigenpulseo.jpg

Aigenpulse

phone +44 (0)2037 735431
email info@aigenpulse.com
web http://www.aigenpulse.com
email 15J Olympic Ave, Park Dr, Milton, Abingdon OX14 4SA

Data Technology as a Catalyst for Growth in the Life Sciences

The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Eurofins Assurance is Expanding its Quality Assurance and GxP Pharma Audit Offering With the Acquisition of Sisthema

1 February 2022, Brussels, Belgium: Eurofins Assurance is pleased to announce the acquisition of Sisthema, a full-serviced quality service provider for the pharma, medical devices and cosmetic industries, as an essential component of its three-year strategic expansion plan.
More info >>


White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement